乐普医疗：收购河南新帅克制药股份有限公司股份可行性研究报告

《乐普医疗：收购河南新帅克制药股份有限公司股份可行性研究报告》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、[收购]乐普医疗：收购河南新帅克制药股份有限公司股份可行性研究报告时间：2013年06月22日15:16:40 中财网收购河南新帅克制药股份有限公司股份可行性研究报告乐普（北京）医疗器械股份有限公司2013年06月目录第一节项目的必要性与可行性···············································································1一、项目实施是乐普医疗产品多元化战略发展的必然选择··································

2、·······1二、项目对乐普医疗未来发展将产生重大影响························································1三、新帅克在国内心血管药物领域的竞争优势························································2四、医改政策有利于心血管药物快速发展······························································2五、协同效应令人期待········

3、··············································································3第二节国内外市场分析························································································4一、国内外医药行业发展趋势······································································

4、·······4二、我国化学药行业分析···················································································6三、新帅克核心产品市场分析·············································································7第三节技术分析····························································

5、····································14一、我国化学药技术发展历史············································································14二、我国药品审批现状·····················································································15三、新帅克的产品创新与研发······················

6、······················································15第四节竞争力分析·····························································································17一、硫酸氢氯吡格雷片竞争分析·········································································17二、复方甘草酸苷片竞争分析

7、············································································19三、全身抗感染药物竞争分析············································································20四、其他产品竞争分析··················································································

8、···20五、竞争力分析······························································································21第五节公司概况··························································